FilingReader Intelligence
Hengrui Pharma: Strong 2024 results, expands pipeline, prioritizes innovation
March 31, 2025 at 07:08 AM UTC•By FilingReader AI
Jiangsu Hengrui Medicine (SSE:600276) announced its 2024 financial results, highlighting a strong commitment to innovation and global expansion. The company reported a 22.63% year-over-year increase in revenue, reaching CNY 27.98 billion, and a 47.28% surge in net profit attributable to shareholders, totaling CNY 6.34 billion. The company allocated CNY 8.23 billion for R&D.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Hengrui Medicine 2024 Annual ReportMarch 30, 2025 at 07:46 AM UTC
Hengrui Medicine's announcement on the inclusion of drugs in the public list of proposed breakthrough therapiesMarch 30, 2025 at 08:33 AM UTC
Hengrui Medicine's announcement on obtaining approval for drug clinical trialsMarch 26, 2025 at 08:52 AM UTC
Hengrui Medicine's announcement on obtaining approval for drug clinical trialsMarch 27, 2025 at 08:58 AM UTC
Hengrui Medicine's shareholder dividend return plan for the next three years (2025-2027)March 30, 2025 at 07:46 AM UTC
Hengrui Medicine 2024 Annual Report SummaryMarch 30, 2025 at 07:46 AM UTC
Hengrui Medicine's announcement on reappointment of accounting firmMarch 30, 2025 at 07:46 AM UTC
Special statement on the occupation of non-operating funds and other related-party capital transactions of Jiangsu Hengrui Medicine Co., Ltd. in 2024March 30, 2025 at 07:46 AM UTC
Hengrui Medicine 2024 Internal Control Evaluation ReportMarch 30, 2025 at 07:46 AM UTC
Hengrui Medicine 2024 Internal Control Audit ReportMarch 30, 2025 at 07:46 AM UTC
Hengrui Medicine 2024 Environmental, Social and Governance ReportMarch 30, 2025 at 07:46 AM UTC
Announcement of Hengrui Medicine's 2024 Profit Distribution PlanMarch 30, 2025 at 07:46 AM UTC
News Alerts
Get instant email alerts when Jiangsu Hengrui Medicine publishes news
Free account required • Unsubscribe anytime